Immunocytochemical study of the expression of mesothelin in fine-needle aspiration biopsy specimens of pancreatic adenocarcinoma

Diagnostic Cytopathology

Volumn 35, Issue 3, 2007, Pages 143-147

  Baruch, Amy C ^a   Wang, Huamin ^a   Staerkel, Gregg A ^a   Evans, Douglas B ^a   Hwang, Rosa Frances ^a   Krishnamurthy, Savitri ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Fine needle aspiration biopsy; Mesothelin; Pancreas

Indexed keywords

MESOTHELIN; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MALE; PANCREAS ADENOCARCINOMA; PAPANICOLAOU TEST; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOPSY, FINE-NEEDLE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PANCREAS; PANCREATIC NEOPLASMS; VAGINAL SMEARS;

EID: 33847659592     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.20594     Document Type: Article

References (21)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Mitchell ML, Carney C. Cytologic criteria for the diagnois of pancreatic carcinoma. Am J Clin Pathol 1985;83:171-176.
3. Fekete PS, Nunez C, Pitlik DA. Fine-needle aspiration biopsy of the pancreas: A study of 61 cases. Diagn Cytopathol 1986;2:301-306.
4. Al-Kaisi N, Siegler EE. Fine needle aspiration cytology of the pancreas. Acta Cytol 1989;33:145-152.
5. Kocjan G, Rode J, Lees WR. Percutaneous fine needle aspiration cytology of the pancreas: Advantages and pitfalls. J Clin Pathol 1989;42:341-347.
6. Robins DB, Katz RL, Evans DB, et al. Fine needle aspiration of the pancreas. In quest of accuracy. Acta Cytol 1995;39:1-10.
7. David O, Green L, Reddy V, et al. Pancreatic masses: A multi-institutional study of 364 fine-needle aspiration biopsies with histopathologic correlation. Diagn Cytopathol 1998;19:423-427.
8. Lin F, Staerkel G. Cytologic criteria for well differentiated adenocarcinoma of the pancreas in fine-needle aspiration biopsy specimens. Cancer 2003;99:44-50.
9. McCarthy DM, Maitra A, Argani P, et al. Novel markers of pancreatic adenocarcinoma in fine-needle aspiration: Mesothelin and prostate stem cell antigen labeling increases accuracy in cytologically borderline cases. Appl Immunohistochem Mol Morphol 2003;11: 238-243.
10. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 1996;93:136-140.
11. Frierson HF, Jr, Moskaluk CA, Powell SM, et al. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol 2003;34:605-609.
12. Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2003;27:1418-1428.
13. Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 1992;50:373-381.
14. Kojima T, Oh-eda M, Hattori K, et al. Molecular cloning and expression of megakaryoctye potentiating factor cDNA. J Biol Chem 1995;270:21984-21990.
15. Scholler N, Fu N, Yang Y. et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci USA 1999;96:11531-11536.
16. Argani P, Iacobuzio-Donahue C, Ryu B, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: Identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001;7:3862-3868.
17. Hassan R, Viner JL, Wang QC, Margulies I, Kreitman RJ, Pastan I. Anti-tumor activity of KI-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian caner and malignant mesothelioma. J Immunother 2000;23:473-479.
18. Hassan R, Lerner MR, Benbrook D, et al. Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. Clin Cancer Res 2002;8:3520-3526.
19. Hassan R, Bera T, Pastan I. Mesothelin: A new target for immunotherapy. Clin Cancer Res 2004;15:3937-3942.
20. Hornick JL, Lauwers GY, Odze RD. Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver. Am J Surg Pathol 2005;29:381-389.
21. Dennis JL, Hvidsten TR, Wit EC, et al. Markers of adenocarcinoma characteristic of the site of origin: Development of a diagnostic algorithm. Clin Cancer Res 2005;11:3766-3772.